Sofgen Pharma

Sofgen Pharma EBITDA

Delisted·Sep 1, 2026

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sofgen Pharma (PROCF) as of Oct 15, 2026 is -32.48 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 44.27 M USD — a change of -173.36% (lower).

EBITDA

-32.48 MUSD

YoY

-173.36%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sofgen Pharma is 2024 -32.48 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sofgen Pharma was 2023 44.27 M USD. It decreases by -173.36% lower compared to the previous year.

The Sofgen Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
37.40 M USD
Jan 1, 2020
69.10 M USD
Jan 1, 2021
70.45 M USD
Jan 1, 2022
43.12 M USD
Jan 1, 2023
44.27 M USD
Jan 1, 2024
-32.48 M USD
The Sofgen Pharma EBITDA history
YEAREBITDAYoY
-32.48 MUSD-173.36%
44.27 MUSD+2.69%
43.12 MUSD-38.80%
70.45 MUSD+1.95%
69.10 MUSD+84.76%
37.40 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Sofgen Pharma SA, listed under the ticker PROCF with ISIN LU2376511205, is a pharmaceutical company headquartered in Luxembourg. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Sofgen Pharma employs approximately 5,500 people and completed its initial public offering on December 9, 2019. The company's website is https://www.procapsgroup.com/. Sofgen Pharma SA develops, manufactures, and sells prescription drugs and products featuring unique combinations and pharmaceutical forms, alongside nutritional supplements such as omega-3 fish oils and high-potency clinical compounds. The company organizes its operations through five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics focuses on diabetes solutions. Farma Procaps is involved in formulating, manufacturing, and marketing branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to other pharmaceutical companies. Vital Care specializes in developing, manufacturing, and marketing consumer healthcare products. Clinical Specialties is dedicated to the development, manufacturing, and marketing of complex drugs. The company's business model emphasizes specialized pharmaceutical solutions and consumer health products, with a global operational footprint. Sofgen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sofgen Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sofgen Pharma is -32.48 M USD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sofgen Pharma changed from 44.27 M USD to -32.48 M USD, representing a -173.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sofgen Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sofgen Pharma

All Key Metrics — Sofgen Pharma